Mitch McConnell Slams Trumps 18 Billion Fund as Utterly Stupid Financial and Political Implications Workday Shares Rise on Upgraded Margin Outlook Driven by AI Adoption Charter Communications Revises Liberty Broadband Buyout Proposal Announces Agreed Terms Prediction Markets Boom Why Young Men Drive a MultiBillionDollar Industry Kazatomprom Production Surges 17 in Q3 Bolstering Global Uranium Supply Alaska Air Group Explores Integration of Boeings Virtual Airplane Technology ABVX Q4 2025 Earnings Significant EPS Miss as DevelopmentStage Biotech Reports WiderThanExpected Loss EVC Q1 2026 Earnings Profitable Quarter Drives Positive Market Reaction eGain Q1 2026 Earnings EPS Beats Estimates by Over 54 Weyco Group Q1 2026 Earnings Steady EPS Performance Amid Challenging Retail Environment Gladstone Land Corporation LAND Q1 2026 Earnings EPS Surprises to the Upside Despite Negative Bottom Line Newsmax Inc NMAX Q1 2026 Earnings Narrowing Loss Beats Expectations Amid Revenue Omission IM Cannabis Corp IMCC Surges 157 Key Levels and Market Dynamics ING Group NV ING Edges Lower Amid Modest Pullback Digital Realty Trust DLR Holds Near Resistance as Modest Decline Tests Momentum Travelers TRV Holds Steady Near Support as Market Awaits Catalysts Forafric Global Warrants AFRIW Hold Steady at 075 Amid Quiet Trading Apples Record Rally Faces AI Test at WWDC Next Month Kyivstar Group Ltd KYIV Q1 2026 Earnings EPS Surprises to the Upside Stock Rallies Mount Logan Capital Inc MLCI Slides 33 Amid ProfitTaking Pressure SNFCA Q4 2025 Earnings Earnings per share of 053 reported stock edges lower ITIC Q4 2025 Earnings Strong EPS Reported Amid Market Uncertainty HASI Q1 2026 Earnings EPS Beats Expectations Stock Rises Evotec Q1 2026 Earnings EPS Falls Sharply Short of Estimates Amid Operational Pressures Coursera Q1 2026 Earnings EPS Miss Sends Mixed Signal as Stock Gains American Financial Group Q1 2026 Earnings EPS Misses Estimates Amid Premium Growth Headwinds Processa Pharmaceuticals PCSA Q4 2025 Earnings EPS Misses Estimates by a Wide Margin as PreRevenue Biotech Advances Pipeline